Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine

DOI 10.1038/74704

Cited by (1,006)

Items 201–300 of 1,006

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E K Kohrt, Ariane Thielens, Aurélien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuséri, Cécile Bonnafous, Debra Katherine Czerwinski, Amanda Rajapaksa et al. · 2013 · Blood
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · 2021 · Nature reviews. Cancer
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Debu Tripathy, Dennis J. Slamon, Melody Cobleigh, Andrew Arnold, Mansoor Noorali Saleh, Joanne E. Mortimer, Maureen Murphy, Stanford J. Stewart · 2004 · Journal of Clinical Oncology
The antiinflammatory activity of IgG: the intravenous IgG paradox
Falk Nimmerjahn, Jeffrey V. Ravetch · 2007 · The Journal of Experimental Medicine
Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders
G.A.W. Rook, Victoria Adams, Rebecca Palmer, Laura Rosa Brunet, Jon R. F. Hunt, Roberta Martinelli · 2004 · Springer Seminars in Immunopathology
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
Hideharu Kimura, Kazuko Sakai, Tokuzo Arao, Tatsu Shimoyama, Tomohide Tamura, Kazuto Nishio · 2007 · Cancer Science
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Nuray Gül, Liane Babes, Kerstin Siegmund, Rianne Korthouwer, Marijn Bögels, Rens Braster, Gestur Vidarsson, Timo L.M. ten Hagen, Paul Kubes, Marjolein van Egmond · 2014 · Journal of Clinical Investigation
CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Xi Wen Zhao, Ellen M. van Beek, Karin Schornagel, Hans van der Maaden, Michel van Houdt, Marielle A. Otten, Pascal Finetti, Marjolein van Egmond, Takashi Matozaki, Georg Kraal et al. · 2011 · Proceedings of the National Academy of Sciences
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Katayoun Rezvani, Rayne Helen Rouce · 2015 · Frontiers in Immunology
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Voštiar, Patrick F. Joyce, Roland Repp et al. · 2008 · Cancer Research
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
Cristiana Lo Nigro, Marco Macagno, Dario Sangiolo, Luca Bertolaccini, Massimo Aglietta, Marco Carlo Merlano · 2019 · Annals of Translational Medicine
Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
Lux, Anja, Yu, Xiaojie, Scanlan, Chris N, Nimmerjahn, Falk · 2013 · The Journal of Immunology
M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Marzia Leidi, Elisa Gotti, Luca Bologna, Elena Miranda, Monica Rimoldi, Antonio Sica, Massimo G. Roncalli, Giuseppe A. Palumbo, Martino Introna, Josée Golay · 2009 · The Journal of Immunology
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Xuanming Yang, Xunmin Zhang, May Lynne Fu, Ralph R. Weichselbaum, Thomas F. Gajewski, Yajun Guo, Yang‐Xin Fu · 2014 · Cancer Cell
Targeting HER2 for the Treatment of Breast Cancer
Mothaffar Fahed Rimawi, Rachel Schiff, Charles Kent Osborne · 2015 · Annual Review of Medicine
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo, Jeffrey V. Ravetch · 2015 · Cell
Targeting HER-2/ neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion
Brian J. Czerniecki, Gary K. Koski, Ursula Koldovsky, Shuwen Xu, Peter A. Cohen, Rosemarie Mick, Harvey L. Nisenbaum, Terry Pasha, Min Xu, Kevin R. Fox et al. · 2007 · Cancer Research
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
Sean H. Lim, Andrew T. Vaughan, Margaret Ashton‐Key, Emily L. Williams, Sandra V. Dixon, H.T. Claude Chan, Stephen A. Beers, Ruth R. French, Kerry L. Cox, Andrew John Davies et al. · 2011 · Blood
Immune complex–mediated antigen presentation induces tumor immunity
Khadija Rafiq, Amy Bergtold, Raphael Clynes · 2002 · Journal of Clinical Investigation
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Yuan Tang, Yue Wang, Mohammad F. Kiani, Bin Wang · 2016 · Clinical Breast Cancer
Complement function in mAb-mediated cancer immunotherapy
Kyra A. Gelderman, Stephen Tomlinson, Gordon D. Ross, Arko Gorter · 2004 · Trends in Immunology
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz, Frank J M Beurskens, Paul V. Beum, Margaret A. Lindorfer, Jan G. J. van de Winkel, Paul W.H.I. Parren, Ronald P. Taylor · 2009 · The Journal of Immunology
Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types
Andrea M. Griesinger, Diane K. Birks, Andrew M. Donson, Vladimir M. Amani, Lindsey Marie Hoffman, Allen E. Waziri, Michael Wang, Michael H. Handler, Nicholas K. Foreman · 2013 · The Journal of Immunology
Mechanism of action of trastuzumab and scientific update
Jose M Baselga, Joan Albanell, Miguel Angel Molina, Joaquı́n Arribas · 2001 · Seminars in Oncology
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
Sandra J. Horning, Anas Younes, Vinay Kumar Jain, S. Kroll, Jennifer B. Lucas, Donald A. Podoloff, Michael L. Goris · 2004 · Journal of Clinical Oncology
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
Wenle Xia, Catherine M. Gerard, Lei-Hua Liu, Nathalie Baudson, T. Ory, Neil L. Spector · 2005 · Oncogene
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
Brischwein, Klaus, Schlereth, Bernd, Guller, Benjamin, Steiger, Carola, Wolf, Andreas, Lutterbuese, Ralf, Offner, Sonja, Locher, Mathias, Urbig, Thomas, Raum, Tobias et al. · 2006 · Molecular Immunology
Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications
Cynthia Osborne, P. Wilson, Debu Tripathy · 2004 · The Oncologist
Mechanisms of action of CD20 antibodies.
Péter Boross, Jeanette H.W. Leusen · 2012 · PubMed Central
Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB−/− Mice
Silvia M. Bolland, Young‐Sun Yim, Katalin Tus, Edward K. Wakeland, Jeffrey V. Ravetch · 2002 · The Journal of Experimental Medicine
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Meletios Athanasios Dimopoulos, Constantinos Zervas, Athanassios Zomas, Christos Kiamouris, Nora Athina Viniou, Vassiliki Grigoraki, Christos Karkantaris, Chrisanthi Mitsouli, Dimitra Gika, John I. Christakis et al. · 2002 · Journal of Clinical Oncology
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
Lilach M. Friedman, Ariel Rinon, Bilha Schechter, Ljuba Lyass, Sara Lavi, Sarah S. Bacus, Michael Sela, Yosef Yarden · 2005 · Proceedings of the National Academy of Sciences
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom, Sergey N. Gorlatov, Wenjun Zhang, Yinhua Yang, Ling Huang, Steve Burke, Hua Li, Valentina C. Ciccarone, Téngfēi Zhāng, Jeffrey B. Stavenhagen et al. · 2011 · Breast Cancer Research
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Javier Cortés, P. Fumoleau, Giulia Bianchi, Teresa M. Petrella, Karen A. Gelmon, Xavier B. Pivot, Shailendra Verma, Joan Albanell, PierFranco Conte, Ana M. Lluch et al. · 2012 · Journal of Clinical Oncology
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity
Tom van Meerten, Rozemarijn S. van Rijn, Samantha Hol, Anton Hagenbeek, Saskia B. Ebeling · 2006 · Clinical Cancer Research
Signal transduction during Fc receptor-mediated phagocytosis
Erick García-García, Carlos Rosales · 2002 · Journal of Leukocyte Biology
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Andrea Barretto Motoyama, Nancy E. Hynes, Heidi A. Lane · 2002 · PubMed
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson, Becky Yang, Annie Yang, Stefanie Loeser, Scot A. Marsters, David A. Lawrence, Yun Li, Robert M. Pitti, Klára Tótpál, Sharon Fong Yee et al. · 2011 · Cancer Cell
The mechanisms of action of rituximab in the elimination of tumor cells
Peter Johnson, Martin J. Glennie · 2003 · Seminars in Oncology
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Leonard G. Presta · 2006 · Advanced Drug Delivery Reviews
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors
Yoshikatsu Kaneko, Falk Nimmerjahn, Michael P. Madaio, Jeffrey V. Ravetch · 2006 · The Journal of Experimental Medicine
Functions of Antibodies
Donald N. Forthal · 2014 · Microbiology Spectrum
Pemphigus: Current and Future Therapeutic Strategies
Dario Didona, Roberto Maglie, Rüdiger Eming, Michael Hertl · 2019 · Frontiers in Immunology
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides
Rinpei Niwa, Akito Natsume, Aya Uehara, Masako Wakitani, Shigeru Iida, Kazuhisa Uchida, Mitsuo Satoh, Kenya Shitara · 2005 · Journal of Immunological Methods
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim, Stephen A. Beers, Ruth R. French, Peter Johnson, M J Glennie, Mark Steven Cragg · 2009 · Haematologica
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Rena Liu, Robert J. Oldham, Emma L. Teal, Stephen A. Beers, Mark Steven Cragg · 2020 · Antibodies
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
Kavita M. Dhodapkar, Jacob L. Kaufman, Marc Ehlers, Devi Kanti Banerjee, Ezio Bonvini, Scott Koenig, Ralph M. Steinman, Jeffrey V. Ravetch, Madhav V. Dhodapkar · 2005 · Proceedings of the National Academy of Sciences
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Claudio Vernieri, Monica Milano, Marta Brambilla, Alessia Mennitto, Claudia Maggi, Maria Silvia Cona, Michele Prisciandaro, Chiara Fabbroni, Luigi Celio, Gabriella Mariani et al. · 2019 · Critical Reviews in Oncology/Hematology
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
Stefania Varchetta, Nadia Gibelli, Barbara Oliviero, Elena Nardini, Roberto Gennari, Giovanna Maria Gatti, Luzemira Santos Silva, Laura Villani, Elda Tagliabue, Sylvie Ménard et al. · 2007 · Cancer Research
The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes
Paul V. Beum, Adam D. Kennedy, Michael E. Williams, Margaret A. Lindorfer, Ronald P. Taylor · 2006 · The Journal of Immunology
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
Yasuhito Hamaguchi, Yan Xiu, Kazuhiro Komura, Falk Nimmerjahn, Thomas F. Tedder · 2006 · The Journal of Experimental Medicine
Endocytosis in cancer and cancer therapy
Blerida Banushi, Shannon R. Joseph, Benedict Lum, Jason J. Lee, Fiona Simpson · 2023 · Nature reviews. Cancer
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
Ursula J. E. Seidel, Patrick Schlegel, Peter Lang · 2013 · Frontiers in Immunology
Breast cancer — one term, many entities?
Nicholas Bertos, Morag Park · 2011 · Journal of Clinical Investigation
CD20‐mediated apoptosis: signalling through lipid rafts
Julie P. Deans, Haidong Li, Maria J. Polyak · 2002 · Immunology
Antibodies, Fc receptors and cancer
Falk Nimmerjahn, Jeffrey V. Ravetch · 2007 · Current Opinion in Immunology
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Michael J. Townsend, John G. Monroe, Andrew C. Chan · 2010 · Immunological Reviews
Clinical development of targeted and immune based anti-cancer therapies
Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, Angelica M. Merlot · 2019 · Journal of Experimental & Clinical Cancer Research
Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Márk Barok, Jorma J Isola, Zsuzsanna Pályi‐Krekk, Péter Nagy, István Juhász, György Vereb, Päivikki Kauraniemi, Anita I. Kapanen, Minna Tanner, György Vereb et al. · 2007 · Molecular Cancer Therapeutics
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both GlobalCD20Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Myron Stefan Czuczman, Scott H. Olejniczak, Aruna C. Gowda, Adam S. Kotowski, Arvinder Binder, Harman P. Kaur, Joy Knight, Petr Starostik, Julie P. Deans, Francisco J. Hernandez‐Ilizaliturri · 2008 · Clinical Cancer Research
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
María Carmen Ochoa, Luna Minute, Inmaculada Rodríguez, Saray Garasa, Elísabeth Pérez-Ruiz, Susana Inogés, Ignacio Melero, Pedro Berraondo · 2017 · Immunology and Cell Biology
Immune complex–mediated antigen presentation induces tumor immunity
Khadija Rafiq, Amy Bergtold, Raphael Clynes · 2002 · Journal of Clinical Investigation
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostálek, Iain B. Gardner, Brian M. Gurbaxani, Rachel H. Rose, Manoranjenni Chetty · 2013 · Clinical Pharmacokinetics
The Use of Lentinan for Treating Gastric Cancer
Kenji Ina, Takae Kataoka, Takafumi Ando · 2013 · Anti-Cancer Agents in Medicinal Chemistry
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Yu Kataoka, Toru Mukohara, Hiroyuki Shimada, Nagahiro Saijo, M. Hirai, Hironobu Minami · 2009 · Annals of Oncology
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
Wei Hseun Yeap, Kok Loon Wong, Noriko Shimasaki, Esmeralda Chi Yuan Teo, Jeffrey Kim Siang Quek, Hao Xiang Yong, Colin Phipps Diong, Antonio Bertoletti, Yeh Ching Linn, Siew Cheng Wong · 2016 · Scientific Reports
Signaling by Antibodies: Recent Progress
Stylianos Bournazos, Taia T. Wang, Rony Dahan, Jad Maamary, Jeffrey V. Ravetch · 2017 · Annual Review of Immunology
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Esteban Cruz, Veysel Kayser · 2019 · Biologics
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White, H.T. Claude Chan, Ali Roghanian, Ruth R. French, Christopher Ian Mockridge, Alison L. Tutt, Sandra V. Dixon, Daniel Ajona, J. Sjef Verbeek, Aymen Al‐Shamkhani et al. · 2011 · The Journal of Immunology
Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism
Rinpei Niwa, Shigeki Hatanaka, Emi Shoji-Hosaka, Mikiko Sakurada, Yukari Kobayashi, Aya Uehara, Haruhiko Yokoi, Kazuyasu Nakamura, Kenya Shitara · 2004 · Clinical Cancer Research
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Holbrook E K Kohrt, Roch Houot, Kipp Weiskopf, Matthew Jordan Goldstein, Ferenc A. Scheeren, Debra Katherine Czerwinski, Alexander Dimitrios Colevas, Wen‐Kai Weng, Michael F. Clarke, Robert W. Carlson et al. · 2012 · Journal of Clinical Investigation · Retracted
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
Márk Barok, Minna Tanner, Katri Köninki, Jorma J Isola · 2011 · Breast Cancer Research
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu · 2023 · Molecular Cancer
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
Edouard J. Louis, Z. El Ghoul, Séverine Vermeire, Sébastien Dall’Ozzo, Paul Rutgeerts, Gilles Paintaud, Jacques Bélaïche, Martine De Vos, A. Van Gossum, J.F. Colombel et al. · 2004 · Alimentary Pharmacology & Therapeutics
Fc Receptor-Like Molecules
Randall S. Davis · 2007 · Annual Review of Immunology
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck, Wim K. Bleeker, Michael Dechant, Thomas D. Beyer, Roland Repp, Patrick H.C. van Berkel, Tom Vink, Jan G. J. van de Winkel et al. · 2008 · Blood
Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins
Motoko Takahashi, Yoshio Kuroki, Kazuaki Ohtsubo, Naoyuki Taniguchi · 2009 · Carbohydrate Research
Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
Teemu T. Junttila, Kathryn L. Parsons, Christine Olsson, Yanmei Lu, Yan Xin, Julie Theriault, Lisa Crocker, Oliver Pabonan, Tomasz Baginski, Gloria Meng et al. · 2010 · Cancer Research
Production of human monoclonal antibody in eggs of chimeric chickens
Lei Zhu, Marie‐Cecile van de Lavoir, Jenny Albanese, David O. Beenhouwer, Pina M. Cardarelli, Severino Cuison, David F Deng, Shrikant Vishnu Deshpande, Jennifer H. Diamond, Lynae Green et al. · 2005 · Nature Biotechnology
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalvès · 2019 · Cancers
Interaction sites on human IgG-Fc for FcγR: current models
Roy Jefferis, John Lund · 2002 · Immunology Letters
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Yulia, Kowalski, Piotr S., Huang, Yuxuan, Gonzalez, John T., Heartlein, Michael W., DeRosa, Frank, Delcassian, Derfogail, Anderson, Daniel G. · 2019 · Molecular Therapy
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
Joan Albanell, Jordi Codony, Ana Rovira, Begoña Mellado, Pere Gascón · 2003 · Advances in experimental medicine and biology
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Estrella Mariel Levy, María Paula Roberti, José Mordoh · 2011 · BioMed Research International
Tumor-associated myeloid cells: diversity and therapeutic targeting
Alberto Mantovani, Federica Marchesi, Sébastien Jaillon, Cecília Garlanda, Paola Allavena · 2021 · Cellular and Molecular Immunology
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanism
Irene Munk Pedersen, Anne Mette Buhl, Pia Helene Klausen, Christian H. Geisler, Jesper Jurlander · 2002 · Blood
The Structural Role of Antibody N-Glycosylation in Receptor Interactions
Ganesh Prasad Subedi, Adam W. Barb · 2015 · Structure
Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
Anne Christine W. Vos, Manon E. Wildenberg, Marjolijn Duijvestein, Auke P. Verhaar, Gijs R. VAN DEN BRINK, Daniël W. Hommes · 2010 · Gastroenterology
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Wen‐Kai Weng, Ronald Levy · 2001 · Blood
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Véronique Minard‐Colin, Yan Xiu, Jonathan C. Poe, Mayuka Horikawa, CYNTHIA M.J. MAGRO, Yasuhito Hamaguchi, Karen M. Haas, Thomas F. Tedder · 2008 · Blood
Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells
Isabel Steinhauser, Birgit Spänkuch, Klaus Strebhardt, Klaus Langer · 2006 · Biomaterials
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clare Taylor, Dawn L. Hershman, Nina D. Shah, Nicole Suciu‐Foca, Dan P. Petrylak, Robert N. Taub, Linda T. Vahdat, Bin Cheng, Mark Daniel Pegram, Keith L. Knutson et al. · 2007 · Clinical Cancer Research
The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice
Yasuhito Hamaguchi, Junji Uchida, Derek W. Cain, Guglielmo M. Venturi, Jonathan C. Poe, Karen M. Haas, Thomas F. Tedder · 2005 · The Journal of Immunology
Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases
William H. Rastetter, Arturo Molina, Christine A. White · 2004 · Annual Review of Medicine
CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.
H.T. Claude Chan, David Hughes, Ruth R. French, Alison L. Tutt, Claire A. Walshe, Jessica L. Teeling, Martin J. Glennie, Mark Steven Cragg · 2003 · PubMed
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Minna Taskinen, Marja‐Liisa Karjalainen‐Lindsberg, Heidi Nyman, Leena-Maija Eerola, Sirpa Leppä · 2007 · Clinical Cancer Research
Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer
Nuray Gül, Marjolein van Egmond · 2015 · Cancer Research
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen M. Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Andrel Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn E. Packman et al. · 2020 · Molecular Cancer Therapeutics
Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation
Annemiek B. van Spriel, Jeanette H.W. Leusen, Marjolein van Egmond, Henry B P M Dijkman, Karel J.M. Assmann, Tanya N. Mayadas, Jan G. J. van de Winkel · 2001 · Blood
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
Bharat K. R. Chaganty, Songbo Qiu, Anneliese M. M. Gest, Yang Lü, Cristina Ivan, George A. Călin, Louis M. Weiner, Zhen Fan · 2018 · Cancer Letters